BioSenic S.A. (EBR:BIOS)

Market Cap	1.57M
Revenue (ttm)	2.67M
Net Income (ttm)	-7.44M
Shares Out	652.86M
EPS (ttm)	-0.04
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	599,371
Average Volume	6,220,060
Open	0.0025
Previous Close	0.0024
Day's Range	0.0024 - 0.0025
52-Week Range	0.0012 - 0.0160
Beta	-2.57
RSI	55.12
Earnings Date	Sep 5, 2025

About BioSenic

BioSenic S.A., a biotechnology company, develops cell therapy products and treatments for autoimmune and inflammatory diseases in Belgium and France. The company’s technologies include arsenic trioxide (ATO) and oral arsenic trioxide (OATO) platforms. It also provides medicinal products, including ArsciMed, an intravenous drug to treat autoimmune diseases. In addition, the company develops ArsciCor, an oral medication in Phase III clinical trial and for the treatment for chronic graft-versus-host disease; JTA-004, an intra-articular injectable ...

• Industry: Biotechnology
• Sector: Healthcare
• CEO: François Rieger
• Employees: 2
• Stock Exchange: Euronext Brussels
• Ticker Symbol: BIOS

Financial Performance

In 2023, BioSenic's revenue was 336,000, an increase of 13.51% compared to the previous year's 296,000. Losses were -28.78 million, 1310.0% more than in 2022.